Acute myeloid leukemia (AML) is a malignancy of stem cells with an unlimited capacity for self-renewal. MUC1 is a secreted, oncogenic mucin that is expressed aberrantly in AML blasts, but its potential uses to target AML stem cells have not been explored. Here we report that MUC1 is highly expressed on AML CD34+/lineage-/CD38-cells as compared to their normal stem cell counterparts. MUC1 expression was not restricted to AML CD34+ populations as similar results were obtained with leukemic cells from patients with CD34-disease.
Introduction
Acute myelogenous leukemia (AML) is a clonal disorder of hematopoietic stem cells that have an unrestrained proliferative capacity (1, 2) . Patients with AML often achieve complete remissions with induction chemotherapy; however, the majority relapse and succumb to their disease (3) . The leukemic stem cell (LSC) population is considered to be resistant to chemotherapy and responsible for disease relapse (2) . LSCs have been characterized by a CD34+/CD38-phenotype and the capability of generating leukemia in immunodeficient mice (4, 5) . Nonetheless, the leukemic CD34+/CD38-cell population can be heterogenous and include normal hematopoietic stem cells. LSCs can also exhibit varying levels of CD34 and CD38 expression (6, 7) .
Moreover, AML CD34-populations have been shown to contain leukemiainitiating cells (8) . For these reasons, a functional definition of leukemic engraftment in immunocompromized mice has been adopted to further define the LSC population (7) (8) (9) . Markers of LSCs, such as CD32, CD35, the IL-3 receptor alpha chain and CD47, have been identified based on their selective expression in LSCs compared to normal hematopoietic stem cells (10) (11) (12) . In addition, CD32-and CD35-positive LSCs initiate AML in mice and exhibit chemoresistance in vivo (12) . Intermediate levels of aldehyde dehydrogenase (ALDH) activity have also been incorporated to distinguish CD34+/CD38-LSCs from their normal counterparts that exhibit relatively higher levels of activity (13) Author Manuscript Published OnlineFirst on July 18, 2013; DOI: 10.1158/0008-5472.CAN- patients (14, 15) . MUC1 is translated as a single polypeptide that undergoes autocleavage into two subunits which in turn form a stable noncovalent heterodimer (16) . The MUC1 N-terminal subunit (MUC1-N) is the glycosylated mucin component of the heterodimer that resides at the cell surface in a complex with the C-terminal transmembrane subunit (MUC1-C) (16) . MUC1-C includes a 58-amino acid (aa) extracellular domain, a 28-aa transmembrane domain and a 72-aa cytoplasmic tail. The MUC1-C subunit interacts with receptor tyrosine kinases (RTKs) at the cell membrane and localizes to the nucleus where it interacts with transcription factors, such as NF-NB and the E-catenin/TCF4 complex, that have been linked to transformation (17) (18) (19) . Localization of MUC1-C to the nucleus is dependent on the formation of homodimers through a CQC motif in the MUC1-C cytoplasmic tail (20) . Accordingly, the cellpenetrating peptide, designated GO-203, was developed that binds to the CQC motif and blocks MUC1-C homodimerization and function (21) .
Treatment of AML cell lines and primary blasts with GO-203 was associated with increases in reactive oxygen species (ROS), arrest of growth and induction of terminal differentiation (21) . These findings provided support for the MUC1-C subunit as a target for inhibiting the self-renewal capacity of AML cells.
The present studies demonstrate that MUC1 is highly expressed by leukemic CD34+/lineage-/CD38-and CD34-/lineage-cells as compared to normal hematopoietic stem cells. We show that the AML MUC1
high , but not MUC1 low , cells initiate AML in the NSG mouse model and that treatment with the MUC1-C inhibitor depletes engrafted AML cells in vivo. expression, CD34+ cells were isolated using the MiniMacs CD34 cell isolation kit (Miltenyi Biotec). As controls, CD34+ populations were isolated from (i) mobilized peripheral blood stem cell products obtained from healthy donors and (ii) bone marrow aspirates from patients with lymphoid malignancies without evidence of marrow involvement. For in vivo experiments, CD34+/lineage-and CD34-/lineage-cells were isolated from bone marrow samples from patients with AML using flow cytometric sorting (FACSAria). Lineage-is defined as negative for CD3, CD14, CD16, CD19, CD20 and CD56. (Fig. 3A) . The MUC1 high cells were inoculated into NSG mice, which were then followed for 90 days. encountered with certain AML samples (9, 11, 23 (Fig. 4B) . Moreover, the few CD34+/lineage-MUC1 low cells had a normal karyotype (Fig. 4B ) and thereby represented residual normal hematopoietic stem cells. The isolated lineage-MUC1 high cells were inoculated into 6 NSG mice and, after 90 days, the bone marrows were analyzed for AML engraftment.
Analysis of a bone marrow from a representative mouse demonstrated the presence of 36% human CD45+ cells (Fig. 4C, left ) that all expressed human CD11C and not CD20 (Fig. 4C, right) , consistent with a myeloid phenotype. Morphology of the human CD45+/CD11C cells was also consistent with AML cells (Fig. 4D, left) . Moreover, the engrafted hCD45+/hCD11C population had the MLL gene rearrangement, in concert with the leukemic genotype (Fig. 4D, right) . Notably, all of the 6 
additional 70 days. Analysis of the bone marrow from a PBS-treated mouse demonstrated the presence of human CD45+ cells (Fig. 5A, left) that were also CD34+ (Fig. 5A, right) . By contrast, analysis of the bone marrow from a GO-203-treated mouse demonstrated few if any detectable human CD45+/CD34+ cells (Fig. 5B, left and right) . As compared to the control mice, treatment with GO-203 abrogated leukemic engraftment in 4 of the 5 GO-203-treated mice (Fig. 5C ). The bone marrow from the 5 th mouse treated with GO-203 had 1.9% involvement of the mononuclear population with human CD45+/CD34+ cells (Fig. 5C ).
Bone marrows of the GO-203-treated mice had a mean of 0.5% involvement with leukemic cells as compared to 27% for the 5 PBS-treated mice ( in the peripheral blood. Treatment with PBS and GO-203 was continued for 21 days, at which time the mice were sacrificed for analysis. The bone marrow of a representative PBS-treated mouse had 74% involvement with hCD45+ cells that also expressed hCD11C and not hCD20 (Fig. 6A,   left) , and had a leukemic cell morphology. Similar findings were obtained for involvement of leukemic cells in the spleen (Supplemental Fig. S2A) . In a representative GO-203-treated mouse, there were few if any hCD45+ cells in the bone marrow (Fig. 6A, right) and 0.4% involvement of hCD20+ cells in the spleen (Supplemental Fig. S2B) . associated with a marked decrease in leukemic cell involvement (Fig.   6E , right) that was significantly different from that found in the bone marrows of the PBS-treated mice (Fig. 6F) . 
Discussion
MUC1 is a heterodimeric glycoprotein that is expressed on the apical borders of normal epithelial cells (16) . With progression to carcinomas and loss of polarity, MUC1 is aberrantly expressed at high levels over the entire cell surface and contributes to the malignant phenotype (16, 25) . Somewhat surprisingly for this epithelial cell protein, expression of MUC1 was identified in blasts from AML patients (14) . In addition, subsequent studies showed that MUC1 is detectable in certain CD34+ cells found in human cord blood and at higher levels in AML CD34+ populations (15) . In the present work, AML CD34+/lineage-/CD38-cells from patients with active disease were studied to determine whether this population, which has been associated with (27, 28) . However, the CD34+/CD38-population can include normal hematopoietic stem cells, invoking the possibility that MUC1 expression as detected here could be also attributable to this population. In that sense, we found that CD34+/lineage-/CD38-cells from transplant donors express MUC1, but at low to undetectable levels. Indeed, the fraction of MUC1+ normal CD34+/lineage-/CD38-cells was less than 3%, indicating that MUC1 expression is substantially higher in the leukemic CD34+/lineage-/CD38-population. The CD34+/CD38-cell phenotype has been associated with leukemiainitiating cells that give rise to CD34+/CD38+ progenitors and more differentiated blasts (5) . In certain AML samples, the leukemic CD34+/CD38+ progenitor population also contains leukemia-initiating cell capacity (29) . In this respect, we found that CD34+/lineage-/CD38+ progenitor cell populations from AML patients express MUC1 over a similar range of percentages as that obtained for the CD34+/lineage-/CD38-cells. Leukemia-initiating activity has also been identified in 
